000163434 001__ 163434
000163434 005__ 20230915090519.0
000163434 0247_ $$2doi$$a10.1186/s13195-021-00955-9
000163434 0247_ $$2pmid$$apmid:35027079
000163434 0247_ $$2pmc$$apmc:PMC8759265
000163434 0247_ $$2altmetric$$aaltmetric:120884866
000163434 037__ $$aDZNE-2022-00194
000163434 041__ $$aEnglish
000163434 082__ $$a610
000163434 1001_ $$0P:(DE-2719)2812183$$aHermann, Peter$$b0$$udzne
000163434 245__ $$aPlasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers.
000163434 260__ $$aLondon$$bBioMed Central$$c2022
000163434 3367_ $$2DRIVER$$aarticle
000163434 3367_ $$2DataCite$$aOutput Types/Journal article
000163434 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1654865397_23358
000163434 3367_ $$2BibTeX$$aARTICLE
000163434 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163434 3367_ $$00$$2EndNote$$aJournal Article
000163434 520__ $$aLipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer's disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been proposed as a biomarker for Alzheimer's disease but available data is scarce and inconsistent. Thus, we evaluated plasma Lipocalin-2 in the context of Alzheimer's disease, differential diagnoses, other biomarkers, and clinical data.For this two-center case-control study, we analyzed Lipocalin-2 concentrations in plasma samples from a cohort of n = 407 individuals. The diagnostic groups comprised Alzheimer's disease (n = 74), vascular dementia (n = 28), other important differential diagnoses (n = 221), and healthy controls (n = 84). Main results were validated in an independent cohort with patients with Alzheimer's disease (n = 19), mild cognitive impairment (n = 27), and healthy individuals (n = 28).Plasma Lipocalin-2 was significantly lower in Alzheimer's disease compared to healthy controls (p < 0.001) and all other groups (p < 0.01) except for mixed dementia (vascular and Alzheimer's pathologic changes). Areas under the curve from receiver operation characteristics for the discrimination of Alzheimer's disease and healthy controls were 0.783 (95%CI: 0.712-0.855) in the study cohort and 0.766 (95%CI: 0.627-0.905) in the validation cohort. The area under the curve for Alzheimer's disease versus vascular dementia was 0.778 (95%CI: 0.667-0.890) in the study cohort. In Alzheimer's disease patients, plasma Lipocalin2 did not show significant correlation with cerebrospinal fluid biomarkers of neurodegeneration and AD-related pathology (total-tau, phosphorylated tau protein, and beta-amyloid 1-42), cognitive status (Mini Mental Status Examination scores), APOE genotype, or presence of white matter hyperintensities. Interestingly, Lipocalin 2 was lower in patients with rapid disease course compared to patients with non-rapidly progressive Alzheimer's disease (p = 0.013).Plasma Lipocalin-2 has potential as a diagnostic biomarker for Alzheimer's disease and seems to be independent from currently employed biomarkers.
000163434 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163434 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163434 650_7 $$2Other$$aAlzheimer’s disease
000163434 650_7 $$2Other$$aBiomarker
000163434 650_7 $$2Other$$aDementia
000163434 650_7 $$2Other$$aLipocalin 2
000163434 650_7 $$2Other$$aNeutrophil gelatinase-associated Lipocalin
000163434 650_7 $$2Other$$aPlasma
000163434 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000163434 650_7 $$2NLM Chemicals$$aBiomarkers
000163434 650_7 $$2NLM Chemicals$$aLipocalin-2
000163434 650_7 $$2NLM Chemicals$$atau Proteins
000163434 650_2 $$2MeSH$$aAlzheimer Disease: blood
000163434 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000163434 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000163434 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000163434 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000163434 650_2 $$2MeSH$$aBiomarkers: blood
000163434 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000163434 650_2 $$2MeSH$$aCase-Control Studies
000163434 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000163434 650_2 $$2MeSH$$aDiagnosis, Differential
000163434 650_2 $$2MeSH$$aHumans
000163434 650_2 $$2MeSH$$aLipocalin-2: blood
000163434 650_2 $$2MeSH$$atau Proteins
000163434 7001_ $$0P:(DE-2719)9000327$$aVillar-Piqué, Anna$$b1$$udzne
000163434 7001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b2$$udzne
000163434 7001_ $$0P:(DE-2719)9000950$$aSchmidt, Christian$$b3$$udzne
000163434 7001_ $$0P:(DE-2719)9000324$$aVarges, Daniela$$b4$$udzne
000163434 7001_ $$0P:(DE-2719)9001986$$aGoebel, Stefan$$b5$$udzne
000163434 7001_ $$aBunck, Timothy$$b6
000163434 7001_ $$aLindemann, Hanna$$b7
000163434 7001_ $$aBogner, Carla$$b8
000163434 7001_ $$aSantana, Isabel$$b9
000163434 7001_ $$aBaldeiras, Inês$$b10
000163434 7001_ $$aRiggert, Joachim$$b11
000163434 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b12$$eLast author$$udzne
000163434 7001_ $$0P:(DE-2719)2811280$$aLlorens Torres, Francesc Josep$$b13$$udzne
000163434 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-021-00955-9$$gVol. 14, no. 1, p. 9$$n1$$p9$$tAlzheimer's research & therapy$$v14$$x1758-9193$$y2022
000163434 8564_ $$uhttps://pub.dzne.de/record/163434/files/DZNE-2022-00194.pdf$$yOpenAccess
000163434 8564_ $$uhttps://pub.dzne.de/record/163434/files/DZNE-2022-00194.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163434 909CO $$ooai:pub.dzne.de:163434$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2812183$$aExternal Institute$$b0$$kExtern
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000327$$aExternal Institute$$b1$$kExtern
000163434 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000950$$aExternal Institute$$b3$$kExtern
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000324$$aExternal Institute$$b4$$kExtern
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001986$$aExternal Institute$$b5$$kExtern
000163434 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000163434 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811280$$aExternal Institute$$b13$$kExtern
000163434 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163434 9141_ $$y2022
000163434 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000163434 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000163434 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000163434 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000163434 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163434 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000163434 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:57Z
000163434 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:57Z
000163434 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-02-14T16:18:57Z
000163434 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000163434 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000163434 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x0
000163434 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x1
000163434 980__ $$ajournal
000163434 980__ $$aVDB
000163434 980__ $$aUNRESTRICTED
000163434 980__ $$aI:(DE-2719)1440011-1
000163434 980__ $$aI:(DE-2719)5000037
000163434 9801_ $$aFullTexts